Maillard AM, Ruef A, Pizzagalli F, Migliavacca E, Hippolyte L, Adaszewski S, et al. The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity. Mol Psychiatry. 2015;20(1):140-7. DOI: 10.1038/mp.2014.145. PubMed PMID: 25421402.
Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19 Suppl 1:38-52; quiz 35-7, 53. DOI: 10.1017/S1092852914000601. PubMed PMID: 25403863.
Kawada T. Relationship between metabolic syndrome and psychiatric disorders in patients with bipolar disorder or schizophrenia. Bipolar Disord. 2015;17(2):233-4. DOI: 10.1111/bdi.12279. PubMed PMID: 25400223.
Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. Bmc Psychiatry. 2010;10:2. DOI: 10.1186/1471-244X-10-2. PubMed PMID: 20059765; PubMed Central PMCID: PMC2817695.
Dassa D, Boyer L, Benoit M, Bourcet S, Raymondet P, Bottai T. Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system. Aust N Z J Psychiatry. 2010;44(10):921-8. DOI: 10.3109/00048674.2010.493503. PubMed PMID: 20932206.
Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998;8(1):55-66. PubMed PMID: 9452941.
Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry. 2003;64 Suppl 16:34-40. PubMed PMID: 14680417.